Phio Pharmaceuticals Corp. Form 8-K Summary
Business Context and Reporting Period
Phio Pharmaceuticals Corp. (PHIO), a Delaware corporation, filed this Current Report on Form 8-K on August 11, 2022. The filing serves to announce the company's financial results for the period ended June 30, 2022. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached press release (Exhibit 99.1), which is not included in the source text.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. Investors must refer to the attached press release for comparative financial analysis.
Guidance, Outlook, and Risks
This Form 8-K does not include specific guidance, outlook, management commentary, or risk factors within the body of the report. The document explicitly states that the information in Item 2.02 and Exhibit 99.1 is not treated as "filed" for purposes of Section 18 of the Exchange Act and will not be incorporated by reference unless expressly stated in another filing.
Key Facts for Investor Verification
- Verify the specific financial results for the period ended June 30, 2022, by reviewing the press release attached as Exhibit 99.1.
- Confirm the company's cash position and runway, as these are critical for a clinical-stage biopharmaceutical company but are not listed in this summary text.
- Note that the financial data in this filing is not legally "filed" under Section 18 of the Exchange Act, limiting liability protections for the specific numbers contained in the press release.
- Check for any subsequent filings that may incorporate the press release by reference to ensure the data is officially part of the public record.